Skip to content

Replimune Group REPL Change in Other Assets

Change in Other Assets at other companies

Amgen logo
AmgenAMGN
-$8M-104%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$0+100%
Immunome logo
ImmunomeIMNM
$5.1M+199%
CG Oncology logo
CG OncologyCGON
$8.07M+1,377%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
-$3.03M-254%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$3M

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+30.2%
Enterprise value$885.15M+30.0%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentAssets.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's change in other assets?
Replimune Group (REPL) reported change in other assets of $94K in Q4 2025.
How has Replimune Group's change in other assets changed year-over-year?
Replimune Group's change in other assets decreased by 88.1% year-over-year, from $793K to $94K.
What is the long-term trend for Replimune Group's change in other assets?
Over 2 years (2023 to 2025), Replimune Group's change in other assets has grown at a 6.4% compound annual growth rate (CAGR), from $1.06M to $1.2M.
What does change in other assets mean?
Change in miscellaneous assets affecting operating cash flow.